{"gene":"GNAQ","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1997,"finding":"Gαq (GNAQ protein) is essential for platelet activation by physiological platelet activators (thrombin, collagen, ADP, etc.). Mice deficient in Gαq have platelets that are completely unresponsive to these activators, resulting in increased bleeding times and protection from thromboembolism. Gαq cannot be functionally replaced by Gαi or βγ subunits in this context.","method":"Germline knockout mice (Gαq-deficient), platelet aggregation assays, bleeding time measurements, thromboembolism model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with specific platelet activation phenotype, replicated across multiple agonists, published in Nature","pmids":["9296496"],"is_preprint":false},{"year":1998,"finding":"Gαq (and the closely related Gα11) are required for cardiac development: double-knockout mice (Gαq−/−;Gα11−/−) die at embryonic day 11 due to cardiomyocyte hypoplasia, demonstrating an essential and partially redundant role of the Gq class in cardiac growth.","method":"Double-knockout mouse genetics, embryonic lethal phenotype analysis, histology","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-KO with clear embryonic lethal phenotype, multiple allele combinations tested","pmids":["9687499"],"is_preprint":false},{"year":1998,"finding":"Cardiac-specific overexpression of Gαq in transgenic mice stimulates fetal gene expression, depresses cardiomyocyte contractility, and upon pressure overload leads to decompensated eccentric hypertrophy and heart failure, demonstrating that intrinsic Gαq activation is deleterious to cardiac adaptation.","method":"Cardiac-specific transgenic mice overexpressing Gαq (G alpha q-25), transverse aortic coarctation, echocardiography, gene expression analysis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic overexpression with specific cardiac phenotype, multiple functional readouts","pmids":["9576430"],"is_preprint":false},{"year":1996,"finding":"Gαq (and other Gαq family members: Gα11, Gα14, Gα15, Gα16) couples PTH/PTHrP receptor and calcitonin receptor to phospholipase C activation in COS-7 and HEK293 cells, demonstrating that dual signaling of these receptors involves distinct G proteins (Gs for adenylyl cyclase; Gq family for PLC).","method":"Reconstitution in COS-7/HEK293 cells, cotransfection of receptor with Gαq family α-subunit cDNAs, inositol phosphate accumulation assay","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional reconstitution assay in heterologous cells with multiple Gαq family members tested","pmids":["8732687"],"is_preprint":false},{"year":1997,"finding":"The gastrin-releasing peptide receptor (GRPr) selectively couples to Gαq (and not to Gαi/o or Gαt) to catalyze GTP-γS binding. Receptor-catalyzed exchange requires agonist (GRP) and Gβγ subunits; EC50 for GRP was 3.5 nM, consistent with known receptor affinity.","method":"In situ reconstitution assay in chaotrope-extracted fibroblast membranes expressing GRPr; GTP-γS binding with purified Gα subunits; radioligand binding","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified components; selectivity confirmed across multiple Gα subunits","pmids":["9012857"],"is_preprint":false},{"year":1999,"finding":"Gαq plays a required role in insulin-stimulated GLUT4 translocation and glucose transport in adipocytes. Constitutively active Q209L-Gαq stimulates GLUT4 translocation in a wortmannin-sensitive (PI3K-dependent) manner and activates PI3Kα (p110α), and anti-p110α (not anti-p110γ) antibody blocks both insulin- and Q209L-Gαq-induced GLUT4 translocation.","method":"Microinjection of anti-Gαq/11 antibody or RGS2, adenoviral overexpression of WT or Q209L-Gαq, 2-deoxyglucose uptake, immunoprecipitation of PI3K, wortmannin inhibition","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (antibody microinjection, dominant-active overexpression, kinase assay, pharmacological inhibition) in single lab","pmids":["10490615"],"is_preprint":false},{"year":2001,"finding":"Gαq is required for metabotropic glutamate receptor (mGluR)-dependent long-term depression (LTD) in hippocampal CA1, but not for LTP. LTD induced by group I mGluR agonist or by paired-pulse low-frequency stimulation is absent in Gαq-knockout mice; instead, PP-LFS causes potentiation.","method":"Gαq−/− knockout mice, hippocampal slice electrophysiology, LTP/LTD induction protocols, pharmacological receptor agonists","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse, specific synaptic plasticity phenotype with multiple induction protocols and pharmacology","pmids":["11438569"],"is_preprint":false},{"year":2002,"finding":"LARG (leukemia-associated RhoGEF), unlike p115-RhoGEF, interacts with Gαq (as well as Gα12 and Gα13) via its RGS box in co-immunoprecipitation. Activated Gαq cooperates with LARG to cause synergistic activation of RhoA, identifying LARG as an effector linking Gαq-coupled receptors to RhoA signaling.","method":"Cellular co-immunoprecipitation with transition-state mimetic Gα subunits, RhoA activation assays, transforming activity assays, expression of LARG RGS box","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with functional RhoA activation assay; single lab","pmids":["12024019"],"is_preprint":false},{"year":2003,"finding":"GRK2 binds to the active form of Gαq (but not Gα16) via its RGS domain in an activation-dependent manner. The C-terminus of Gαq mediates binding to GRK2. GRK2 is the first RGS protein identified that discriminates between members of the Gαq family.","method":"Immunoprecipitation, GST-GRK2 pull-down, inositol phosphate signaling assay, plasma membrane recruitment assay with GRK2-GFP, chimeric Gαq/16 subunits","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pull-down plus functional assays; C-terminus mapped by chimera; single lab, multiple methods","pmids":["12885252"],"is_preprint":false},{"year":2003,"finding":"Constitutively active Gαq (Q209L) inhibits PI3K activity specifically in p110α (not p110β) immunoprecipitates and co-immunoprecipitates with p110α-p85α heterodimer. In vitro incubation of immunoprecipitated Gαq(Q209L) with purified recombinant p110α-p85α decreases PI3K activity. This inhibition is independent of PLC activation.","method":"Inducible expression of Gαq(Q209L), PI3K activity assay from immunoprecipitates, co-immunoprecipitation, in vitro kinase assay with purified p110α-p85α, PLC inhibitor pretreatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assay with purified components plus cellular co-IP; two orthogonal methods","pmids":["12704201"],"is_preprint":false},{"year":2003,"finding":"The Gbeta5·RGS7 dimer directly interacts with Gαq as shown by FRET between fluorescently tagged proteins in live mammalian cells, and inhibits Gαq/11-mediated signaling. This interaction requires additional cellular factors not present in purified systems.","method":"FRET spectroscopy on cell suspensions and single-cell microscopy, co-immunoprecipitation, functional signaling assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET in live cells plus co-IP and functional assay; single lab","pmids":["12670932"],"is_preprint":false},{"year":2006,"finding":"Gαq and PLCβ1 form a stable pre-associated complex in both unstimulated PC12 and HEK293 cells, as demonstrated by FRET. PLCβ1 binds to both Gαq(GTPγS) and Gαq(GDP) in vitro, but with different protein-protein orientations. Pre-formed complexes give rise to rapid, localized signals upon activation.","method":"FRET in live cells (single-cell imaging and cell suspension), in vitro FRET measurements, quantification of protein levels in transfected cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET in living cells and in vitro; stable pre-association demonstrated at endogenous-like expression levels; single lab","pmids":["16754659"],"is_preprint":false},{"year":2007,"finding":"Gαq is required for the alternative chemokine receptor signaling pathway in dendritic cells and granulocytes. Gαq-deficient neutrophils and DCs show defective calcium responses and chemotaxis to specific chemokines (CCL3 for neutrophils; CCL2, CCL19, CCL21, CXCL12 for DCs), and Gαq-deficient mice show impaired DC migration from skin to lymph nodes.","method":"Gαq-deficient mice, calcium flux assays, transwell chemotaxis assays, in vivo skin sensitization model, bone marrow transplantation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse with both in vitro and in vivo phenotypes across multiple cell types and chemokines","pmids":["17938235"],"is_preprint":false},{"year":2007,"finding":"Gαq activation (via P2Y2 receptor stimulation) inhibits keratinocyte spreading and migration by dismantling the actin network, reducing α3 integrin at the cell periphery, dissolving focal contacts, and blocking growth factor-induced ERK and Akt phosphorylation. These effects were confirmed by YM-254890 (Gαq antagonist), Gαq/11 siRNA knockdown, and constitutively active Q209L-Gαq expression.","method":"Pharmacological inhibition (YM-254890), siRNA knockdown, constitutively active Gαq overexpression, live-cell kymography, immunofluorescence, wound-healing assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — three orthogonal approaches (inhibitor, siRNA, dominant-active mutant) all converging on same phenotype; single lab","pmids":["17609252"],"is_preprint":false},{"year":2007,"finding":"Continuous activation of Gαq in osteoblasts (via Q209L transgene) impairs osteoblast differentiation and causes osteopenia. This effect is mediated via the protein kinase C pathway, as a PKC inhibitor (GF109203X) prevents the impairment of differentiation.","method":"Osteoblast-specific transgenic mice expressing constitutively active Gαq(Q209L), histomorphometry, MC3T3-E1 cell culture, PKC inhibitor rescue","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse plus cell culture with pharmacological rescue; single lab","pmids":["17823129"],"is_preprint":false},{"year":2007,"finding":"Prostaglandin F2α inhibits adipocyte differentiation via a Gαq–Ca2+–calcineurin signaling pathway that blocks expression of pro-adipogenic transcription factors PPARγ and C/EBPα. This mechanism involves an HDAC-sensitive step and does not interfere with mitotic clonal expansion or C/EBPβ.","method":"Gαq/11 functional assays, anti-Gαq/11 antibody, calcineurin inhibitor, HDAC inhibitor (TSA), gene expression analysis, adipogenesis assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors defining pathway order; single lab","pmids":["16888802"],"is_preprint":false},{"year":2008,"finding":"Gαq mutations at codon 209 (in the Ras-like domain) are constitutively activating and turn GNAQ into a dominant oncogene. These somatic mutations occur in 83% of blue naevi and 46% of uveal melanoma, providing an alternative route to MAP kinase activation in melanocytic neoplasia.","method":"Tumor sequencing, cell-based transformation assays with mutant GNAQ constructs demonstrating constitutive activation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — somatic mutation identified and functionally validated as constitutively activating; published in Nature with high citation","pmids":["19078957"],"is_preprint":false},{"year":2008,"finding":"RGS2 and RGS4 form ternary complexes with Gαq and GRK2 (or p63RhoGEF). RGS2 acts as a negative allosteric modulator of Gαq binding to either p63RhoGEF or GRK2. Conversely, GRK2 enhances the GAP activity of RGS4. These findings support GRK2 as a bona fide Gαq effector.","method":"Flow cytometry protein interaction assay (FCPIA), GAP assays, allosteric modulation measurements","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (FCPIA + GAP assay) demonstrating ternary complex formation and allosteric effects; single lab","pmids":["18936096"],"is_preprint":false},{"year":2008,"finding":"Diacylglycerol kinase zeta (DGKζ), which degrades DAG downstream of Gαq-PLCβ signaling, rescues Gαq transgenic mice from heart failure. DGKζ prevents cardiac dysfunction, attenuates PKC isoform translocation, and reduces JNK and p38 MAPK phosphorylation caused by activated Gαq.","method":"Double-transgenic mice (Gαq × DGKζ), echocardiography, PKC translocation assay, kinase phosphorylation assays, survival analysis","journal":"Circulation journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo (double transgenic rescue), multiple molecular readouts; single lab","pmids":["18219172"],"is_preprint":false},{"year":2010,"finding":"Mechanical stretch activates GRK2 in cardiac myocytes via a Gαq–angiotensin II AT1 receptor–PKCα pathway. PKCα phosphorylates GRK2 at Ser29, activating it. A GRK2(S29A) mutant abolishes stretch-induced GRK2 activation and restores adenylyl cyclase activity, defining the phosphorylation mechanism.","method":"Neonatal rat cardiomyocyte stretch model, mini-gene inhibition of Gαq coupling, shRNA knockdown of PKCα, GRK2(S29A) overexpression, cardiac-specific PKCα transgenic mice, adenylyl cyclase activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — phosphorylation site mutagenesis (S29A) combined with KD, transgenic, and cell-stretch model; multiple orthogonal methods","pmids":["20194499"],"is_preprint":false},{"year":2011,"finding":"The Gαq signal (constituted by Gαq and Gα11 in osteoblasts) is inhibitory to the anabolic action of PTH on bone. Osteoblast-specific Gαq/Gα11 double-knockout mice show enhanced PTH-induced bone formation, while constitutively active Gαq transgenic mice do not respond to PTH. The inhibitory mechanism involves membrane translocation of PKCδ.","method":"Osteoblast-specific Gαq/Gα11 double-KO mice, constitutively active Gαq transgenic mice, PTH injection experiments, bone histomorphometry, primary osteoblast cultures, PKCδ translocation assay, RGS2 overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — both gain- and loss-of-function in vivo, cell-autonomous confirmation in primary cultures, PKCδ mechanism identified","pmids":["21345793"],"is_preprint":false},{"year":2013,"finding":"A somatic activating mutation in GNAQ (c.548G→A, p.R183Q) causes Sturge-Weber syndrome and port-wine stains. The R183Q mutation leads to constitutive activation of Gαq, modestly increasing ERK activity as shown by phosphorylation-specific antibodies and luciferase reporter assay upon transgenic expression of mutant Gαq.","method":"Whole-genome sequencing of paired affected/normal tissue, amplicon sequencing and SNaPshot assays in 97 samples, phosphorylation-specific antibodies for ERK, luciferase reporter assay","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — discovery by WGS validated across 97 samples with functional confirmation of downstream signaling activation","pmids":["23656586"],"is_preprint":false},{"year":2013,"finding":"Mutant GNAQ/GNA11 (Q209 mutations) consistently activates both the PKC and MAPK pathways in uveal melanoma cells. PKC inhibition selectively suppresses MAPK signaling in GNAQ/GNA11-mutant (but not wild-type) melanoma, demonstrating that PKC is an intermediary between mutant Gαq and MAPK activation.","method":"PKC inhibitors (AEB071, AHT956), MEK inhibitors (PD0325901, MEK162), cell proliferation and apoptosis assays, western blotting for pathway activation, allograft and xenograft mouse models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological epistasis with two different PKC inhibitors, two MEK inhibitors, in vitro and in vivo; single lab","pmids":["24141786"],"is_preprint":false},{"year":2017,"finding":"In GNAQ-mutant uveal melanoma, MAPK activation depends on Ras and is mediated by RasGRP3, which is overexpressed selectively in response to GNAQ/11 mutation. RasGRP3 activation requires PKCδ- and PKCε-dependent phosphorylation as well as PKC-independent, DAG-mediated membrane recruitment. PKCδ and PKCε are required and sufficient for MAPK activation downstream of mutant Gαq.","method":"shRNA knockdown, PKC isoform-specific analysis, RasGRP3 expression analysis, phosphorylation assays, DAG membrane recruitment assays, MAPK activation readouts","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — specific PKC isoforms identified by KD, mechanistic pathway order established with multiple readouts; single lab","pmids":["28486107"],"is_preprint":false},{"year":2021,"finding":"Endothelial GNAQ p.R183Q constitutively activates PLCβ3 (a direct downstream effector of Gαq), leading to activation of PKC, NF-κB, and calcineurin signaling. This increases ANGPT2 and DSCR1.4 expression. EC-R183Q cells form enlarged blood vessels in mice, and ANGPT2 knockdown normalizes vessel size, identifying PLCβ3→ANGPT2 as a key mechanism for capillary malformation.","method":"Lentiviral expression of R183Q or WT GNAQ in endothelial colony-forming cells, bulk RNA-seq, quantitative PCR, immunostaining of human tissue, YM-254890 inhibitor, PLCβ3 siRNA, PKC inhibitor (AEB071), shRNA knockdown of ANGPT2, in vivo vessel formation assay in mice","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (inhibitors, siRNA, in vivo rescue by ANGPT2 KD), human tissue validation; defines pathway mechanism","pmids":["34670408"],"is_preprint":false},{"year":2023,"finding":"Downstream of GNAQ-mutant Gαq, the RhoA signaling axis activates PKN (PRK, an AGC kinase), which converges with ROCK to control FAK (focal adhesion kinase) as a mediator of non-canonical Gαq-driven signaling. PKN inhibition by darovasertib synergizes with FAK inhibitors to halt uveal melanoma growth.","method":"High-throughput chemogenetic drug screen, kinase inhibitor profiling (darovasertib), PKN/ROCK/FAK pathway analysis, cell viability assays, in vitro and in vivo (mouse metastatic model) combination studies","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chemogenetic screen plus pathway validation with inhibitors; in vitro and preclinical in vivo; single lab","pmids":["37858338"],"is_preprint":false},{"year":2023,"finding":"GNAQ/11 mosaic variants (including R183Q and Q209L) hyperactivate constitutive and ligand-induced intracellular calcium signaling in endothelial cells. The aberrant ligand-activated calcium signal is fueled by extracellular calcium influx through calcium-release-activated channels (CRAC). Allele-selective siRNA targeting the variant allele corrects both constitutive and ligand-activated calcium signaling, and a CRAC inhibitor rescues the ligand-activated signal.","method":"Two cellular models expressing GNAQ/11 variants, intracellular calcium imaging, allele-selective siRNA, CRAC channel inhibitor","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two cellular models, pharmacological and genetic rescue; identifies CRAC channels as mediators; single lab","pmids":["37802293"],"is_preprint":false},{"year":2022,"finding":"Reporter assays comparing GNAQ variants (WT, R183Q, Q209L, Q209R, null) show Q209L has highest activation, while R183Q and Q209R show significantly lower but still activating levels. RNA-seq of microvascular endothelial cells shows all missense variants cause extensive transcriptomic dysregulation compared to WT or null, but R183 and Q209 variants show very few differentially expressed genes when compared to each other — differing in activation magnitude but having similar downstream effects.","method":"GNAQ-responsive luciferase reporter assay, RNA-seq in HMEC-1 cells electroporated with GNAQ variants","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct reporter assay plus RNA-seq in two experimental systems; single lab","pmids":["35635655"],"is_preprint":false},{"year":2016,"finding":"The endothelial cell is the specific cell type enriched for the GNAQ p.R183Q mutation in skin capillary malformations (mutant allelic frequency 3–43% in CD31+ endothelial cells versus lower in other fractions), identifying endothelial cells as the source of aberrant Gαq signaling in capillary malformation.","method":"FACS fractionation of human capillary malformation tissue into endothelial, hematopoietic, perivascular, and stromal populations; droplet digital PCR for GNAQ p.R183Q","journal":"Plastic and reconstructive surgery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific fractionation plus highly sensitive ddPCR; 6 specimens fractionated; single lab","pmids":["26368330"],"is_preprint":false},{"year":2019,"finding":"GNAQ T96S mutation (found in 8.7% of NK/T cell lymphoma) acts in a dominant-negative manner to promote tumor growth by suppressing Gαq-mediated inhibition of AKT and MAPK signaling. Conditional Gαq knockout in NK cells (Ncr1-Cre) demonstrates that Gαq deficiency enhances NK cell survival, identifying Gαq as a tumor suppressor in this context.","method":"Whole-exome/targeted deep sequencing, conditional KO mice (Ncr1-Cre-Gnaqfl/fl), NK cell survival assays, AKT and MAPK pathway activation assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific cellular phenotype and pathway analysis; dominant-negative mechanism proposed with pathway data; single lab","pmids":["31527657"],"is_preprint":false},{"year":2023,"finding":"Hyperactive GNAQ mutation in endothelial cells (mouse model) drives vascular tumor growth with increased MAPK signaling. Trametinib (MEK inhibitor) suppresses tumor growth by reducing vascular cell proliferation and permeability and prevents coagulopathy.","method":"Endothelial-specific hyperactive GNAQ knock-in mouse model, transcriptomic analysis, Trametinib treatment, vascular phenotype and coagulopathy measurement","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse model with transcriptomic pathway validation and pharmacological rescue; single lab","pmids":["37024491"],"is_preprint":false}],"current_model":"GNAQ encodes the Gαq subunit of heterotrimeric G proteins, which couples activated GPCRs to phospholipase Cβ (particularly PLCβ1 and PLCβ3) via a pre-formed, stable complex at the plasma membrane; PLCβ activation generates DAG and IP3, leading to PKC activation and intracellular calcium release (via CRAC channels), with downstream activation of MAPK (through RasGRP3 via PKCδ/ε), RhoA (via LARG), and FAK (via PKN/ROCK); Gαq also inhibits PI3Kα/Akt through direct interaction; its activity is terminated by GRK2 and RGS proteins (RGS2, RGS4) acting allosterically; somatic activating mutations at Q209 (constitutively activating) or R183Q (moderately activating) drive uveal melanoma, blue naevi, and vascular malformations (Sturge-Weber syndrome, capillary malformations) by constitutively engaging these downstream cascades in melanocytes and endothelial cells, respectively, while germline loss-of-function reveals essential roles in platelet activation, cardiac development, hippocampal LTD, and dendritic cell chemotaxis."},"narrative":{"mechanistic_narrative":"GNAQ encodes the Gαq subunit of a heterotrimeric G protein that couples agonist-activated GPCRs to phospholipase C, transducing receptor signals into intracellular calcium, DAG, and PKC activation; it does so selectively, coupling defined receptors such as the PTH/PTHrP, calcitonin, and gastrin-releasing peptide receptors to PLC in a manner that requires agonist and Gβγ and cannot be substituted by Gαi or βγ [PMID:8732687, PMID:9012857, PMID:9296496]. Gαq engages PLCβ1 as a stable pre-associated complex that permits rapid, localized signaling upon activation [PMID:16754659], and it recruits additional effectors including the RhoGEF LARG to activate RhoA [PMID:12024019]; conversely, constitutively active Gαq directly binds and inhibits the p110α–p85α PI3K heterodimer independently of PLC [PMID:12704201]. Its signaling output is constrained by GRK2, which binds active Gαq through its RGS domain in an activation-dependent manner via the Gαq C-terminus and acts as a bona fide effector, together with the Gβ5·RGS7 dimer and RGS2/RGS4, which form ternary complexes and allosterically modulate Gαq engagement of effectors [PMID:12885252, PMID:12670932, PMID:18936096]. Through these cascades Gαq is essential for platelet activation by physiological agonists, for cardiac development, for mGluR-dependent hippocampal long-term depression, and for chemokine-driven calcium responses and chemotaxis in dendritic cells and granulocytes [PMID:9296496, PMID:9687499, PMID:11438569, PMID:17938235], and sustained Gαq activation drives cardiac hypertrophy and heart failure through DAG/PKC-dependent signaling that diacylglycerol kinase ζ can reverse [PMID:9576430, PMID:18219172]. Somatic activating mutations at codon Q209 turn GNAQ into a dominant oncogene in blue naevi and uveal melanoma, while the weaker R183Q mutation causes Sturge-Weber syndrome and capillary malformations; both activate downstream PKC–MAPK signaling via RasGRP3 and PKCδ/ε, RhoA–PKN/ROCK–FAK, and in endothelial cells PLCβ3-driven calcium influx through CRAC channels and ANGPT2 induction [PMID:19078957, PMID:23656586, PMID:24141786, PMID:28486107, PMID:34670408, PMID:37858338, PMID:37802293]. In a contrasting context, the GNAQ T96S mutation acts dominant-negatively to relieve Gαq-mediated suppression of AKT/MAPK, identifying Gαq as a tumor suppressor in NK/T cell lymphoma [PMID:31527657].","teleology":[{"year":1996,"claim":"Established that Gαq is a functional PLC-coupling transducer for specific peptide-hormone GPCRs, defining its core molecular role of linking receptors to inositol phosphate generation.","evidence":"Receptor/Gα cotransfection reconstitution in COS-7/HEK293 with inositol phosphate accumulation assays","pmids":["8732687"],"confidence":"High","gaps":["Did not establish endogenous receptor pairings in native cells","Did not resolve selectivity among Gαq family members in vivo"]},{"year":1997,"claim":"Resolved which receptors selectively recruit Gαq and showed agonist- and Gβγ-dependence of receptor-catalyzed nucleotide exchange, defining the biochemical activation step.","evidence":"In situ reconstitution with purified Gα subunits and GTP-γS binding for the GRP receptor","pmids":["9012857"],"confidence":"High","gaps":["Limited to a single receptor in reconstituted membranes","Did not link to downstream effector engagement"]},{"year":1997,"claim":"Demonstrated a non-redundant physiological requirement for Gαq in platelet activation, showing Gαi and βγ cannot substitute, and connecting Gαq to hemostasis.","evidence":"Germline Gαq-knockout mice with platelet aggregation, bleeding time, and thromboembolism assays","pmids":["9296496"],"confidence":"High","gaps":["Did not map the receptors/effectors mediating the platelet defect","Whole-body KO confounds cell-autonomy"]},{"year":1998,"claim":"Defined Gq-class requirement and redundancy in cardiac development and showed that excess Gαq activity is pathogenic, framing the dosage-sensitive role of Gαq in the heart.","evidence":"Gαq/Gα11 double-KO embryonic lethality and cardiac-specific Gαq overexpression transgenics with pressure overload","pmids":["9687499","9576430"],"confidence":"High","gaps":["Did not isolate the effector branch responsible for hypertrophy","Redundancy with Gα11 obscures Gαq-specific contributions"]},{"year":1999,"claim":"Linked Gαq to PI3K-dependent metabolic signaling, showing constitutively active Gαq drives GLUT4 translocation via p110α.","evidence":"Antibody microinjection, Q209L overexpression, PI3K immunoprecipitation, and wortmannin inhibition in adipocytes","pmids":["10490615"],"confidence":"High","gaps":["Apparent positive PI3K link contrasts with later direct-inhibition finding","Did not establish endogenous receptor input"]},{"year":2001,"claim":"Established a required role for Gαq in synaptic plasticity, specifically mGluR-dependent hippocampal LTD but not LTP.","evidence":"Hippocampal slice electrophysiology in Gαq-KO mice with pharmacological and stimulation-based LTD/LTP induction","pmids":["11438569"],"confidence":"High","gaps":["Did not define the downstream effector chain for LTD","Constitutive KO precludes acute/developmental separation"]},{"year":2002,"claim":"Identified LARG as an effector coupling Gαq to RhoA, extending Gαq output beyond PLCβ to cytoskeletal/Rho signaling.","evidence":"Reciprocal co-IP with transition-state-mimetic Gα and RhoA activation/transformation assays","pmids":["12024019"],"confidence":"Medium","gaps":["Single-lab co-IP without structural mapping of the interaction","Physiological relevance in tissue not established"]},{"year":2003,"claim":"Clarified signal termination/effector machinery by showing GRK2 binds active Gαq via its RGS domain and Gβ5·RGS7 directly engages and inhibits Gαq.","evidence":"Pull-downs, chimeric Gαq mapping, FRET in live cells, and signaling assays","pmids":["12885252","12670932"],"confidence":"Medium","gaps":["Gβ5·RGS7 interaction requires unidentified cellular cofactors","GRK2's dual effector/regulator roles not fully reconciled"]},{"year":2003,"claim":"Demonstrated a PLC-independent branch in which active Gαq directly inhibits p110α PI3K, defining a distinct biochemical effector relationship.","evidence":"In vitro kinase assays with purified p110α-p85α plus cellular co-IP using inducible Q209L-Gαq","pmids":["12704201"],"confidence":"High","gaps":["Reconciliation with the adipocyte GLUT4/PI3K activation finding unresolved","Structural basis of inhibition not determined"]},{"year":2006,"claim":"Showed Gαq and PLCβ1 exist as a stable pre-formed complex, explaining the rapid, localized kinetics of Gq signaling.","evidence":"Live-cell and in vitro FRET at near-endogenous expression in PC12/HEK293 cells","pmids":["16754659"],"confidence":"Medium","gaps":["Single-lab FRET without orthogonal structural confirmation","Stoichiometry and membrane microdomain context not defined"]},{"year":2007,"claim":"Extended Gαq's physiological roles to immune cell migration, cytoskeletal control, and tissue-specific differentiation, showing context-dependent effector use (PKC, calcineurin).","evidence":"Gαq-KO mice (DC/neutrophil chemotaxis), inhibitor/siRNA/Q209L approaches in keratinocytes, and transgenic/pharmacology in osteoblasts and adipocytes","pmids":["17938235","17609252","17823129","16888802"],"confidence":"High","gaps":["Receptor inputs vary by tissue and were not uniformly mapped","Downstream effector convergence across cell types not unified"]},{"year":2008,"claim":"Identified GNAQ Q209 mutations as constitutively activating oncogenic drivers in melanocytic neoplasia, establishing GNAQ as a dominant oncogene.","evidence":"Tumor sequencing of blue naevi/uveal melanoma with cell-based transformation/activation assays","pmids":["19078957"],"confidence":"High","gaps":["Did not delineate the full downstream effector requirements for transformation","Cell-of-origin specificity not addressed"]},{"year":2008,"claim":"Refined Gαq's regulatory network and cardiac pathology mechanism: RGS2/RGS4–GRK2 ternary complexes allosterically modulate Gαq, and DAG kinase ζ rescues Gαq-driven heart failure.","evidence":"FCPIA/GAP assays for allosteric modulation and Gαq×DGKζ double-transgenic mouse rescue with PKC/MAPK readouts","pmids":["18936096","18219172"],"confidence":"Medium","gaps":["Single-lab biochemistry for ternary complexes","DGKζ rescue does not prove DAG is the sole pathogenic node"]},{"year":2010,"claim":"Defined a mechanotransduction circuit in which Gαq–AT1R–PKCα phosphorylates GRK2 at Ser29 to activate it, mechanistically linking Gαq signaling to GRK2 regulation.","evidence":"Cardiomyocyte stretch model with mini-gene Gαq inhibition, PKCα shRNA, GRK2-S29A mutant, and transgenic mice","pmids":["20194499"],"confidence":"High","gaps":["Specific to cardiac stretch context","Did not address feedback on Gαq signaling output"]},{"year":2011,"claim":"Established that Gαq/11 signaling antagonizes PTH anabolic action in bone via PKCδ translocation, demonstrating bidirectional control by gain- and loss-of-function in vivo.","evidence":"Osteoblast-specific Gαq/Gα11 double-KO and Q209L transgenic mice with PTH challenge, histomorphometry, and PKCδ assays","pmids":["21345793"],"confidence":"High","gaps":["Receptor coupling to the inhibitory output not fully mapped","Cross-talk with Gs/cAMP arm not resolved"]},{"year":2013,"claim":"Identified the weaker R183Q activating mutation as the cause of Sturge-Weber syndrome and port-wine stains, expanding GNAQ disease beyond melanoma and linking mutation strength to phenotype.","evidence":"Whole-genome and amplicon sequencing of affected tissue with ERK phosphorylation and luciferase reporter validation","pmids":["23656586"],"confidence":"High","gaps":["Endothelial mechanism not yet defined at this stage","Quantitative relationship of activation strength to phenotype unresolved"]},{"year":2013,"claim":"Defined PKC as the obligatory intermediary between mutant Gαq and MAPK in uveal melanoma, establishing a therapeutically actionable signaling axis.","evidence":"Pharmacological epistasis with PKC and MEK inhibitors plus in vitro/in vivo melanoma models","pmids":["24141786"],"confidence":"High","gaps":["Did not identify the specific Ras pathway link (addressed later)","PKC isoform specificity unresolved at this stage"]},{"year":2016,"claim":"Pinpointed the endothelial cell as the cell type harboring GNAQ R183Q in capillary malformations, identifying the source of aberrant Gαq signaling.","evidence":"FACS fractionation of human malformation tissue with droplet digital PCR for R183Q","pmids":["26368330"],"confidence":"Medium","gaps":["Small specimen number","Did not establish the downstream endothelial mechanism"]},{"year":2017,"claim":"Resolved the Ras-dependent route to MAPK in GNAQ-mutant melanoma, showing RasGRP3 (induced by mutant Gαq) is activated by PKCδ/ε phosphorylation and DAG-mediated recruitment.","evidence":"shRNA knockdown, PKC isoform analysis, DAG recruitment, and MAPK readouts in uveal melanoma cells","pmids":["28486107"],"confidence":"High","gaps":["Single-lab; relative contribution of PKC-dependent vs DAG-dependent recruitment not quantified","Generality across other Gαq-mutant tissues untested"]},{"year":2019,"claim":"Revealed a context-dependent tumor-suppressor role for Gαq, where the dominant-negative T96S mutation relieves Gαq-mediated inhibition of AKT/MAPK to promote NK/T lymphoma.","evidence":"Sequencing, conditional Ncr1-Cre Gαq KO mice, and NK cell survival/pathway assays","pmids":["31527657"],"confidence":"Medium","gaps":["Dominant-negative mechanism inferred from pathway data, not structurally proven","Single-lab; reconciliation with oncogenic Gαq roles incomplete"]},{"year":2022,"claim":"Quantified the activation hierarchy of GNAQ variants, showing R183 and Q209 mutations differ mainly in activation magnitude while producing similar downstream transcriptomes.","evidence":"GNAQ-responsive luciferase reporter and RNA-seq across variant panel in microvascular endothelial cells","pmids":["35635655"],"confidence":"Medium","gaps":["Reporter readout may not capture all effector branches","Phenotypic divergence despite similar transcriptomes unexplained"]},{"year":2023,"claim":"Defined effector mechanisms and therapeutic vulnerabilities of mutant Gαq across vascular and melanoma contexts: endothelial PLCβ3→ANGPT2 and CRAC-mediated calcium influx in malformations, RhoA→PKN/ROCK→FAK in melanoma, and MAPK-driven vascular tumor growth.","evidence":"Endothelial R183Q/knock-in models, RNA-seq, allele-selective siRNA, CRAC/PKC/MEK/PKN/FAK inhibitors, ANGPT2 knockdown, and in vivo rescue","pmids":["34670408","37858338","37802293","37024491"],"confidence":"Medium","gaps":["Each mechanism shown largely single-lab","Relative dominance of parallel effector branches per tissue not integrated"]},{"year":null,"claim":"How the multiple parallel Gαq effector branches (PLCβ/PKC-MAPK, RhoA-FAK, direct PI3K inhibition, CRAC-calcium) are differentially weighted to produce distinct cell-type- and mutation-specific phenotypes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking effector usage to tissue-specific outcome","Structural basis distinguishing R183Q vs Q209 signaling magnitude not defined","Reconciliation of Gαq's oncogenic vs tumor-suppressor roles across cell types incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,4,0]},{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[4,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,21,22,29]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0]}],"complexes":["Gq heterotrimeric G protein"],"partners":["PLCB1","PLCB3","GRK2","ARHGEF12","PIK3CA","RGS2","RGS4","GNB5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50148","full_name":"Guanine nucleotide-binding protein G(q) subunit alpha","aliases":["Guanine nucleotide-binding protein alpha-q"],"length_aa":359,"mass_kda":42.1,"function":"Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:34556863, PubMed:35672283, PubMed:37991948). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (PubMed:37991948). Signaling by an activated GPCR promotes GDP release and GTP binding (PubMed:37991948). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (PubMed:37991948). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:37991948). Signaling is mediated via phospholipase C-beta-dependent inositol lipid hydrolysis for signal propagation: activates phospholipase C-beta: following GPCR activation, GNAQ activates PLC-beta (PLCB1, PLCB2, PLCB3 or PLCB4), leading to production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (PubMed:37991948). Required for platelet activation (By similarity). Regulates B-cell selection and survival and is required to prevent B-cell-dependent autoimmunity (By similarity). Regulates chemotaxis of BM-derived neutrophils and dendritic cells (in vitro) (By similarity). Transduces FFAR4 signaling in response to long-chain fatty acids (LCFAs) (PubMed:27852822). Together with GNA11, required for heart development (By similarity)","subcellular_location":"Cell membrane; Golgi apparatus; Nucleus; Nucleus membrane","url":"https://www.uniprot.org/uniprotkb/P50148/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNAQ","classification":"Not Classified","n_dependent_lines":194,"n_total_lines":1208,"dependency_fraction":0.1605960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"GNB1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GNAQ","total_profiled":1310},"omim":[{"mim_id":"620874","title":"ADHESION G PROTEIN-COUPLED RECEPTOR F5; ADGRF5","url":"https://www.omim.org/entry/620874"},{"mim_id":"618448","title":"G PROTEIN-COUPLED RECEPTOR 139; GPR139","url":"https://www.omim.org/entry/618448"},{"mim_id":"616984","title":"NEUROPEPTIDE VF PRECURSOR; NPVF","url":"https://www.omim.org/entry/616984"},{"mim_id":"615706","title":"AURICULOCONDYLAR SYNDROME 3; ARCND3","url":"https://www.omim.org/entry/615706"},{"mim_id":"613572","title":"G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 6, MEMBER A; GPRC6A","url":"https://www.omim.org/entry/613572"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nuclear speckles","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GNAQ"},"hgnc":{"alias_symbol":["G-ALPHA-q","GAQ"],"prev_symbol":[]},"alphafold":{"accession":"P50148","domains":[{"cath_id":"3.40.50.300","chopping":"44-66_186-349","consensus_level":"medium","plddt":94.6942,"start":44,"end":349},{"cath_id":"1.10.400.10","chopping":"68-180","consensus_level":"medium","plddt":97.7727,"start":68,"end":180}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50148","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50148-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50148-F1-predicted_aligned_error_v6.png","plddt_mean":93.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNAQ","jax_strain_url":"https://www.jax.org/strain/search?query=GNAQ"},"sequence":{"accession":"P50148","fasta_url":"https://rest.uniprot.org/uniprotkb/P50148.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50148/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50148"}},"corpus_meta":[{"pmid":"19078957","id":"PMC_19078957","title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19078957","citation_count":1232,"is_preprint":false},{"pmid":"23656586","id":"PMC_23656586","title":"Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23656586","citation_count":737,"is_preprint":false},{"pmid":"9296496","id":"PMC_9296496","title":"Defective platelet activation in G alpha(q)-deficient mice.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9296496","citation_count":452,"is_preprint":false},{"pmid":"18719078","id":"PMC_18719078","title":"Oncogenic mutations in GNAQ occur early in uveal melanoma.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/18719078","citation_count":270,"is_preprint":false},{"pmid":"9687499","id":"PMC_9687499","title":"Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha q/G alpha 11-mutant mice.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9687499","citation_count":205,"is_preprint":false},{"pmid":"24141786","id":"PMC_24141786","title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24141786","citation_count":162,"is_preprint":false},{"pmid":"9576430","id":"PMC_9576430","title":"Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice.","date":"1998","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/9576430","citation_count":161,"is_preprint":false},{"pmid":"10490615","id":"PMC_10490615","title":"G alpha-q/11 protein plays a key role in insulin-induced glucose transport in 3T3-L1 adipocytes.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10490615","citation_count":145,"is_preprint":false},{"pmid":"12024019","id":"PMC_12024019","title":"Leukemia-associated Rho guanine nucleotide exchange factor promotes G alpha q-coupled activation of RhoA.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12024019","citation_count":136,"is_preprint":false},{"pmid":"28486107","id":"PMC_28486107","title":"RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.","date":"2017","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/28486107","citation_count":131,"is_preprint":false},{"pmid":"26778290","id":"PMC_26778290","title":"Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26778290","citation_count":130,"is_preprint":false},{"pmid":"27058448","id":"PMC_27058448","title":"Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27058448","citation_count":127,"is_preprint":false},{"pmid":"12077299","id":"PMC_12077299","title":"Interaction of G alpha(12) with G alpha(13) and G alpha(q) signaling pathways.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12077299","citation_count":102,"is_preprint":false},{"pmid":"26368330","id":"PMC_26368330","title":"Endothelial Cells from Capillary Malformations Are Enriched for Somatic GNAQ Mutations.","date":"2016","source":"Plastic and reconstructive surgery","url":"https://pubmed.ncbi.nlm.nih.gov/26368330","citation_count":98,"is_preprint":false},{"pmid":"25304237","id":"PMC_25304237","title":"GNAQ and GNA11 mutations in uveal melanoma.","date":"2014","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/25304237","citation_count":97,"is_preprint":false},{"pmid":"25374402","id":"PMC_25374402","title":"The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome.","date":"2014","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25374402","citation_count":93,"is_preprint":false},{"pmid":"26113083","id":"PMC_26113083","title":"Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26113083","citation_count":81,"is_preprint":false},{"pmid":"22653968","id":"PMC_22653968","title":"Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.","date":"2012","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22653968","citation_count":81,"is_preprint":false},{"pmid":"8732687","id":"PMC_8732687","title":"G alpha q family members couple parathyroid hormone (PTH)/PTH-related peptide and calcitonin receptors to phospholipase C in COS-7 cells.","date":"1996","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8732687","citation_count":79,"is_preprint":false},{"pmid":"28809862","id":"PMC_28809862","title":"GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28809862","citation_count":76,"is_preprint":false},{"pmid":"28084343","id":"PMC_28084343","title":"Recurrent GNAQ mutations in anastomosing hemangiomas.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/28084343","citation_count":73,"is_preprint":false},{"pmid":"16888802","id":"PMC_16888802","title":"Prostaglandin F2alpha inhibits adipocyte differentiation via a G alpha q-calcium-calcineurin-dependent signaling pathway.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16888802","citation_count":73,"is_preprint":false},{"pmid":"34385710","id":"PMC_34385710","title":"Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34385710","citation_count":69,"is_preprint":false},{"pmid":"31730812","id":"PMC_31730812","title":"Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31730812","citation_count":66,"is_preprint":false},{"pmid":"16754659","id":"PMC_16754659","title":"Stable association between G alpha(q) and phospholipase C beta 1 in living cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16754659","citation_count":65,"is_preprint":false},{"pmid":"17938235","id":"PMC_17938235","title":"Identification of an alternative G{alpha}q-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17938235","citation_count":65,"is_preprint":false},{"pmid":"9012857","id":"PMC_9012857","title":"Selective reconstitution of gastrin-releasing peptide receptor with G alpha q.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9012857","citation_count":61,"is_preprint":false},{"pmid":"29975248","id":"PMC_29975248","title":"Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm.","date":"2018","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29975248","citation_count":60,"is_preprint":false},{"pmid":"27919468","id":"PMC_27919468","title":"Somatic GNAQ Mutation is Enriched in Brain Endothelial Cells in Sturge-Weber Syndrome.","date":"2016","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27919468","citation_count":60,"is_preprint":false},{"pmid":"12885252","id":"PMC_12885252","title":"Differential interaction of GRK2 with members of the G alpha q family.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12885252","citation_count":58,"is_preprint":false},{"pmid":"12704201","id":"PMC_12704201","title":"Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12704201","citation_count":56,"is_preprint":false},{"pmid":"11438569","id":"PMC_11438569","title":"G(alpha)q-deficient mice lack metabotropic glutamate receptor-dependent long-term depression but show normal long-term potentiation in the hippocampal CA1 region.","date":"2001","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11438569","citation_count":56,"is_preprint":false},{"pmid":"10728414","id":"PMC_10728414","title":"Alterations in Ca2+ cycling proteins and G alpha q signaling after left ventricular assist device support in failing human hearts.","date":"2000","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/10728414","citation_count":55,"is_preprint":false},{"pmid":"17374744","id":"PMC_17374744","title":"G(alpha)q-mediated regulation of TASK3 two-pore domain potassium channels: the role of protein kinase C.","date":"2007","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17374744","citation_count":54,"is_preprint":false},{"pmid":"26399561","id":"PMC_26399561","title":"Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.","date":"2015","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26399561","citation_count":53,"is_preprint":false},{"pmid":"35697803","id":"PMC_35697803","title":"Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35697803","citation_count":51,"is_preprint":false},{"pmid":"11606208","id":"PMC_11606208","title":"Coupling of endothelin receptors to the ERK/MAP kinase pathway. Roles of palmitoylation and G(alpha)q.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11606208","citation_count":51,"is_preprint":false},{"pmid":"26397223","id":"PMC_26397223","title":"BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26397223","citation_count":51,"is_preprint":false},{"pmid":"27815595","id":"PMC_27815595","title":"Gaq proteins: molecular pharmacology and therapeutic potential.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27815595","citation_count":50,"is_preprint":false},{"pmid":"34670408","id":"PMC_34670408","title":"Endothelial GNAQ p.R183Q Increases ANGPT2 (Angiopoietin-2) and Drives Formation of Enlarged Blood Vessels.","date":"2021","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34670408","citation_count":50,"is_preprint":false},{"pmid":"9066988","id":"PMC_9066988","title":"Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder.","date":"1997","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9066988","citation_count":44,"is_preprint":false},{"pmid":"32933997","id":"PMC_32933997","title":"Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32933997","citation_count":43,"is_preprint":false},{"pmid":"30204251","id":"PMC_30204251","title":"GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.","date":"2018","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30204251","citation_count":43,"is_preprint":false},{"pmid":"23634288","id":"PMC_23634288","title":"Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.","date":"2013","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23634288","citation_count":43,"is_preprint":false},{"pmid":"17609252","id":"PMC_17609252","title":"G alpha(q/11)-coupled P2Y2 nucleotide receptor inhibits human keratinocyte spreading and migration.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17609252","citation_count":42,"is_preprint":false},{"pmid":"17287516","id":"PMC_17287516","title":"G alpha(q)-coupled muscarinic acetylcholine receptors enhance nicotinic acetylcholine receptor signaling in Caenorhabditis elegans mating behavior.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17287516","citation_count":41,"is_preprint":false},{"pmid":"7840138","id":"PMC_7840138","title":"G alpha q and G alpha 13 regulate NHE-1 and intracellular calcium in epithelial cells.","date":"1995","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7840138","citation_count":40,"is_preprint":false},{"pmid":"31189994","id":"PMC_31189994","title":"High frequency of GNA14, GNAQ, and GNA11 mutations in cherry hemangioma: a histopathological and molecular study of 85 cases indicating GNA14 as the most commonly mutated gene in vascular neoplasms.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/31189994","citation_count":39,"is_preprint":false},{"pmid":"18936096","id":"PMC_18936096","title":"Assembly of high order G alpha q-effector complexes with RGS proteins.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18936096","citation_count":38,"is_preprint":false},{"pmid":"20805136","id":"PMC_20805136","title":"Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas.","date":"2010","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/20805136","citation_count":38,"is_preprint":false},{"pmid":"22074401","id":"PMC_22074401","title":"Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22074401","citation_count":37,"is_preprint":false},{"pmid":"28779688","id":"PMC_28779688","title":"Computational analysis for GNAQ mutations: New insights on the molecular etiology of Sturge-Weber syndrome.","date":"2017","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/28779688","citation_count":36,"is_preprint":false},{"pmid":"28700778","id":"PMC_28700778","title":"Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28700778","citation_count":35,"is_preprint":false},{"pmid":"12670932","id":"PMC_12670932","title":"G beta 5.RGS7 inhibits G alpha q-mediated signaling via a direct protein-protein interaction.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12670932","citation_count":35,"is_preprint":false},{"pmid":"9011762","id":"PMC_9011762","title":"G alpha q/11 mediates neurotensin excitation of substantia nigra dopaminergic neurons.","date":"1996","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9011762","citation_count":35,"is_preprint":false},{"pmid":"30422215","id":"PMC_30422215","title":"Association of Somatic GNAQ Mutation With Capillary Malformations in a Case of Choroidal Hemangioma.","date":"2019","source":"JAMA ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/30422215","citation_count":34,"is_preprint":false},{"pmid":"26368812","id":"PMC_26368812","title":"Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26368812","citation_count":33,"is_preprint":false},{"pmid":"32064597","id":"PMC_32064597","title":"GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.","date":"2020","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32064597","citation_count":32,"is_preprint":false},{"pmid":"23599145","id":"PMC_23599145","title":"Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23599145","citation_count":32,"is_preprint":false},{"pmid":"11673455","id":"PMC_11673455","title":"G alpha(q/11) coupled to mammalian phospholipase C beta 3-like enzyme mediates the ginsenoside effect on Ca(2+)-activated Cl(-) current in the Xenopus oocyte.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11673455","citation_count":31,"is_preprint":false},{"pmid":"27148356","id":"PMC_27148356","title":"Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.","date":"2016","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27148356","citation_count":29,"is_preprint":false},{"pmid":"31527657","id":"PMC_31527657","title":"Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31527657","citation_count":29,"is_preprint":false},{"pmid":"35635655","id":"PMC_35635655","title":"A novel somatic mutation in GNAQ in a capillary malformation provides insight into molecular pathogenesis.","date":"2022","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/35635655","citation_count":29,"is_preprint":false},{"pmid":"29725622","id":"PMC_29725622","title":"Somatic GNAQ mutation in the forme fruste of Sturge-Weber syndrome.","date":"2018","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29725622","citation_count":29,"is_preprint":false},{"pmid":"31707589","id":"PMC_31707589","title":"GNA11 joins GNAQ and GNA14 as a recurrently mutated gene in anastomosing hemangioma.","date":"2019","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31707589","citation_count":28,"is_preprint":false},{"pmid":"20194499","id":"PMC_20194499","title":"G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20194499","citation_count":28,"is_preprint":false},{"pmid":"21056896","id":"PMC_21056896","title":"Somatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi.","date":"2010","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21056896","citation_count":28,"is_preprint":false},{"pmid":"19121805","id":"PMC_19121805","title":"Diacylglycerol kinase zeta inhibits G(alpha)q-induced atrial remodeling in transgenic mice.","date":"2008","source":"Heart rhythm","url":"https://pubmed.ncbi.nlm.nih.gov/19121805","citation_count":27,"is_preprint":false},{"pmid":"17823129","id":"PMC_17823129","title":"Continuous activation of G alpha q in osteoblasts results in osteopenia through impaired osteoblast differentiation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17823129","citation_count":27,"is_preprint":false},{"pmid":"17664271","id":"PMC_17664271","title":"Tumor necrosis factor receptor-1 can function through a G alpha q/11-beta-arrestin-1 signaling complex.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17664271","citation_count":27,"is_preprint":false},{"pmid":"30870248","id":"PMC_30870248","title":"A somatic missense mutation in GNAQ causes capillary malformation.","date":"2019","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30870248","citation_count":26,"is_preprint":false},{"pmid":"29332123","id":"PMC_29332123","title":"BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.","date":"2018","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/29332123","citation_count":26,"is_preprint":false},{"pmid":"37024491","id":"PMC_37024491","title":"MEK inhibition reduced vascular tumor growth and coagulopathy in a mouse model with hyperactive GNAQ.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37024491","citation_count":26,"is_preprint":false},{"pmid":"29570931","id":"PMC_29570931","title":"Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.","date":"2018","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/29570931","citation_count":25,"is_preprint":false},{"pmid":"20861238","id":"PMC_20861238","title":"Hypothalamic paraventricular nucleus G alpha q subunit protein pathways mediate vasopressin dysregulation and fluid retention in salt-sensitive rats.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20861238","citation_count":25,"is_preprint":false},{"pmid":"30537484","id":"PMC_30537484","title":"GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas.","date":"2018","source":"Ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/30537484","citation_count":24,"is_preprint":false},{"pmid":"28571101","id":"PMC_28571101","title":"GNAQ Mutation in the Venous Vascular Malformation and Underlying Brain Tissue in Sturge-Weber Syndrome.","date":"2017","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/28571101","citation_count":24,"is_preprint":false},{"pmid":"35580369","id":"PMC_35580369","title":"In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.","date":"2022","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/35580369","citation_count":24,"is_preprint":false},{"pmid":"18219172","id":"PMC_18219172","title":"Diacylglycerol kinase zeta rescues G alpha q-induced heart failure in transgenic mice.","date":"2008","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/18219172","citation_count":23,"is_preprint":false},{"pmid":"9398737","id":"PMC_9398737","title":"Pituitary adenomas: screening for G alpha q mutations.","date":"1997","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9398737","citation_count":23,"is_preprint":false},{"pmid":"25280020","id":"PMC_25280020","title":"Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25280020","citation_count":23,"is_preprint":false},{"pmid":"16843638","id":"PMC_16843638","title":"Differential effects of RGS proteins on G alpha(q) and G alpha(11) activity.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16843638","citation_count":23,"is_preprint":false},{"pmid":"31336681","id":"PMC_31336681","title":"GNAQ Q209R Mutations Are Highly Specific for Circumscribed Choroidal Hemangioma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31336681","citation_count":23,"is_preprint":false},{"pmid":"34040639","id":"PMC_34040639","title":"GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34040639","citation_count":23,"is_preprint":false},{"pmid":"37858338","id":"PMC_37858338","title":"High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37858338","citation_count":22,"is_preprint":false},{"pmid":"31173078","id":"PMC_31173078","title":"Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31173078","citation_count":22,"is_preprint":false},{"pmid":"30320917","id":"PMC_30320917","title":"The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30320917","citation_count":22,"is_preprint":false},{"pmid":"29209985","id":"PMC_29209985","title":"Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/29209985","citation_count":21,"is_preprint":false},{"pmid":"36405075","id":"PMC_36405075","title":"GNAQ mutations drive port wine birthmark-associated Sturge-Weber syndrome: A review of pathobiology, therapies, and current models.","date":"2022","source":"Frontiers in human neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36405075","citation_count":21,"is_preprint":false},{"pmid":"25653058","id":"PMC_25653058","title":"Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.","date":"2015","source":"Biomedical microdevices","url":"https://pubmed.ncbi.nlm.nih.gov/25653058","citation_count":21,"is_preprint":false},{"pmid":"38532508","id":"PMC_38532508","title":"MRC1 and LYVE1 expressing macrophages in vascular beds of GNAQ p.R183Q driven capillary malformations in Sturge Weber syndrome.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38532508","citation_count":20,"is_preprint":false},{"pmid":"37098137","id":"PMC_37098137","title":"Developmental expression of the Sturge-Weber syndrome-associated genetic mutation in Gnaq: a formal test of Happle's paradominant inheritance hypothesis.","date":"2023","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37098137","citation_count":20,"is_preprint":false},{"pmid":"21345793","id":"PMC_21345793","title":"G alpha(q) signal in osteoblasts is inhibitory to the osteoanabolic action of parathyroid hormone.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21345793","citation_count":20,"is_preprint":false},{"pmid":"9316442","id":"PMC_9316442","title":"Dexamethasone increases G alpha q-11 expression and hormone-stimulated phospholipase C activity in UMR-106-01 cells.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9316442","citation_count":19,"is_preprint":false},{"pmid":"37802293","id":"PMC_37802293","title":"GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37802293","citation_count":18,"is_preprint":false},{"pmid":"35065460","id":"PMC_35065460","title":"Targeting GNAQ in hypothalamic nerve cells to regulate seasonal estrus in sheep.","date":"2022","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/35065460","citation_count":18,"is_preprint":false},{"pmid":"31680437","id":"PMC_31680437","title":"GNAQQ209L expression initiated in multipotent neural crest cells drives aggressive melanoma of the central nervous system.","date":"2019","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/31680437","citation_count":18,"is_preprint":false},{"pmid":"35512098","id":"PMC_35512098","title":"MITF deficiency accelerates GNAQ-driven uveal melanoma.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35512098","citation_count":17,"is_preprint":false},{"pmid":"23159116","id":"PMC_23159116","title":"BRAF and GNAQ mutations in melanocytic tumors of the oral cavity.","date":"2012","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/23159116","citation_count":17,"is_preprint":false},{"pmid":"25030020","id":"PMC_25030020","title":"GNAQ mutation in a patient with metastatic mucosal melanoma.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25030020","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53959,"output_tokens":8122,"usd":0.141853,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18086,"output_tokens":6446,"usd":0.12579,"stage2_stop_reason":"end_turn"},"total_usd":0.267643,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Gαq (GNAQ protein) is essential for platelet activation by physiological platelet activators (thrombin, collagen, ADP, etc.). Mice deficient in Gαq have platelets that are completely unresponsive to these activators, resulting in increased bleeding times and protection from thromboembolism. Gαq cannot be functionally replaced by Gαi or βγ subunits in this context.\",\n      \"method\": \"Germline knockout mice (Gαq-deficient), platelet aggregation assays, bleeding time measurements, thromboembolism model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with specific platelet activation phenotype, replicated across multiple agonists, published in Nature\",\n      \"pmids\": [\"9296496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Gαq (and the closely related Gα11) are required for cardiac development: double-knockout mice (Gαq−/−;Gα11−/−) die at embryonic day 11 due to cardiomyocyte hypoplasia, demonstrating an essential and partially redundant role of the Gq class in cardiac growth.\",\n      \"method\": \"Double-knockout mouse genetics, embryonic lethal phenotype analysis, histology\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-KO with clear embryonic lethal phenotype, multiple allele combinations tested\",\n      \"pmids\": [\"9687499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Cardiac-specific overexpression of Gαq in transgenic mice stimulates fetal gene expression, depresses cardiomyocyte contractility, and upon pressure overload leads to decompensated eccentric hypertrophy and heart failure, demonstrating that intrinsic Gαq activation is deleterious to cardiac adaptation.\",\n      \"method\": \"Cardiac-specific transgenic mice overexpressing Gαq (G alpha q-25), transverse aortic coarctation, echocardiography, gene expression analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic overexpression with specific cardiac phenotype, multiple functional readouts\",\n      \"pmids\": [\"9576430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Gαq (and other Gαq family members: Gα11, Gα14, Gα15, Gα16) couples PTH/PTHrP receptor and calcitonin receptor to phospholipase C activation in COS-7 and HEK293 cells, demonstrating that dual signaling of these receptors involves distinct G proteins (Gs for adenylyl cyclase; Gq family for PLC).\",\n      \"method\": \"Reconstitution in COS-7/HEK293 cells, cotransfection of receptor with Gαq family α-subunit cDNAs, inositol phosphate accumulation assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional reconstitution assay in heterologous cells with multiple Gαq family members tested\",\n      \"pmids\": [\"8732687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The gastrin-releasing peptide receptor (GRPr) selectively couples to Gαq (and not to Gαi/o or Gαt) to catalyze GTP-γS binding. Receptor-catalyzed exchange requires agonist (GRP) and Gβγ subunits; EC50 for GRP was 3.5 nM, consistent with known receptor affinity.\",\n      \"method\": \"In situ reconstitution assay in chaotrope-extracted fibroblast membranes expressing GRPr; GTP-γS binding with purified Gα subunits; radioligand binding\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified components; selectivity confirmed across multiple Gα subunits\",\n      \"pmids\": [\"9012857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Gαq plays a required role in insulin-stimulated GLUT4 translocation and glucose transport in adipocytes. Constitutively active Q209L-Gαq stimulates GLUT4 translocation in a wortmannin-sensitive (PI3K-dependent) manner and activates PI3Kα (p110α), and anti-p110α (not anti-p110γ) antibody blocks both insulin- and Q209L-Gαq-induced GLUT4 translocation.\",\n      \"method\": \"Microinjection of anti-Gαq/11 antibody or RGS2, adenoviral overexpression of WT or Q209L-Gαq, 2-deoxyglucose uptake, immunoprecipitation of PI3K, wortmannin inhibition\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (antibody microinjection, dominant-active overexpression, kinase assay, pharmacological inhibition) in single lab\",\n      \"pmids\": [\"10490615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Gαq is required for metabotropic glutamate receptor (mGluR)-dependent long-term depression (LTD) in hippocampal CA1, but not for LTP. LTD induced by group I mGluR agonist or by paired-pulse low-frequency stimulation is absent in Gαq-knockout mice; instead, PP-LFS causes potentiation.\",\n      \"method\": \"Gαq−/− knockout mice, hippocampal slice electrophysiology, LTP/LTD induction protocols, pharmacological receptor agonists\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse, specific synaptic plasticity phenotype with multiple induction protocols and pharmacology\",\n      \"pmids\": [\"11438569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"LARG (leukemia-associated RhoGEF), unlike p115-RhoGEF, interacts with Gαq (as well as Gα12 and Gα13) via its RGS box in co-immunoprecipitation. Activated Gαq cooperates with LARG to cause synergistic activation of RhoA, identifying LARG as an effector linking Gαq-coupled receptors to RhoA signaling.\",\n      \"method\": \"Cellular co-immunoprecipitation with transition-state mimetic Gα subunits, RhoA activation assays, transforming activity assays, expression of LARG RGS box\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with functional RhoA activation assay; single lab\",\n      \"pmids\": [\"12024019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GRK2 binds to the active form of Gαq (but not Gα16) via its RGS domain in an activation-dependent manner. The C-terminus of Gαq mediates binding to GRK2. GRK2 is the first RGS protein identified that discriminates between members of the Gαq family.\",\n      \"method\": \"Immunoprecipitation, GST-GRK2 pull-down, inositol phosphate signaling assay, plasma membrane recruitment assay with GRK2-GFP, chimeric Gαq/16 subunits\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pull-down plus functional assays; C-terminus mapped by chimera; single lab, multiple methods\",\n      \"pmids\": [\"12885252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Constitutively active Gαq (Q209L) inhibits PI3K activity specifically in p110α (not p110β) immunoprecipitates and co-immunoprecipitates with p110α-p85α heterodimer. In vitro incubation of immunoprecipitated Gαq(Q209L) with purified recombinant p110α-p85α decreases PI3K activity. This inhibition is independent of PLC activation.\",\n      \"method\": \"Inducible expression of Gαq(Q209L), PI3K activity assay from immunoprecipitates, co-immunoprecipitation, in vitro kinase assay with purified p110α-p85α, PLC inhibitor pretreatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assay with purified components plus cellular co-IP; two orthogonal methods\",\n      \"pmids\": [\"12704201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The Gbeta5·RGS7 dimer directly interacts with Gαq as shown by FRET between fluorescently tagged proteins in live mammalian cells, and inhibits Gαq/11-mediated signaling. This interaction requires additional cellular factors not present in purified systems.\",\n      \"method\": \"FRET spectroscopy on cell suspensions and single-cell microscopy, co-immunoprecipitation, functional signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET in live cells plus co-IP and functional assay; single lab\",\n      \"pmids\": [\"12670932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Gαq and PLCβ1 form a stable pre-associated complex in both unstimulated PC12 and HEK293 cells, as demonstrated by FRET. PLCβ1 binds to both Gαq(GTPγS) and Gαq(GDP) in vitro, but with different protein-protein orientations. Pre-formed complexes give rise to rapid, localized signals upon activation.\",\n      \"method\": \"FRET in live cells (single-cell imaging and cell suspension), in vitro FRET measurements, quantification of protein levels in transfected cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET in living cells and in vitro; stable pre-association demonstrated at endogenous-like expression levels; single lab\",\n      \"pmids\": [\"16754659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Gαq is required for the alternative chemokine receptor signaling pathway in dendritic cells and granulocytes. Gαq-deficient neutrophils and DCs show defective calcium responses and chemotaxis to specific chemokines (CCL3 for neutrophils; CCL2, CCL19, CCL21, CXCL12 for DCs), and Gαq-deficient mice show impaired DC migration from skin to lymph nodes.\",\n      \"method\": \"Gαq-deficient mice, calcium flux assays, transwell chemotaxis assays, in vivo skin sensitization model, bone marrow transplantation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse with both in vitro and in vivo phenotypes across multiple cell types and chemokines\",\n      \"pmids\": [\"17938235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Gαq activation (via P2Y2 receptor stimulation) inhibits keratinocyte spreading and migration by dismantling the actin network, reducing α3 integrin at the cell periphery, dissolving focal contacts, and blocking growth factor-induced ERK and Akt phosphorylation. These effects were confirmed by YM-254890 (Gαq antagonist), Gαq/11 siRNA knockdown, and constitutively active Q209L-Gαq expression.\",\n      \"method\": \"Pharmacological inhibition (YM-254890), siRNA knockdown, constitutively active Gαq overexpression, live-cell kymography, immunofluorescence, wound-healing assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal approaches (inhibitor, siRNA, dominant-active mutant) all converging on same phenotype; single lab\",\n      \"pmids\": [\"17609252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Continuous activation of Gαq in osteoblasts (via Q209L transgene) impairs osteoblast differentiation and causes osteopenia. This effect is mediated via the protein kinase C pathway, as a PKC inhibitor (GF109203X) prevents the impairment of differentiation.\",\n      \"method\": \"Osteoblast-specific transgenic mice expressing constitutively active Gαq(Q209L), histomorphometry, MC3T3-E1 cell culture, PKC inhibitor rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse plus cell culture with pharmacological rescue; single lab\",\n      \"pmids\": [\"17823129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Prostaglandin F2α inhibits adipocyte differentiation via a Gαq–Ca2+–calcineurin signaling pathway that blocks expression of pro-adipogenic transcription factors PPARγ and C/EBPα. This mechanism involves an HDAC-sensitive step and does not interfere with mitotic clonal expansion or C/EBPβ.\",\n      \"method\": \"Gαq/11 functional assays, anti-Gαq/11 antibody, calcineurin inhibitor, HDAC inhibitor (TSA), gene expression analysis, adipogenesis assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors defining pathway order; single lab\",\n      \"pmids\": [\"16888802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Gαq mutations at codon 209 (in the Ras-like domain) are constitutively activating and turn GNAQ into a dominant oncogene. These somatic mutations occur in 83% of blue naevi and 46% of uveal melanoma, providing an alternative route to MAP kinase activation in melanocytic neoplasia.\",\n      \"method\": \"Tumor sequencing, cell-based transformation assays with mutant GNAQ constructs demonstrating constitutive activation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — somatic mutation identified and functionally validated as constitutively activating; published in Nature with high citation\",\n      \"pmids\": [\"19078957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RGS2 and RGS4 form ternary complexes with Gαq and GRK2 (or p63RhoGEF). RGS2 acts as a negative allosteric modulator of Gαq binding to either p63RhoGEF or GRK2. Conversely, GRK2 enhances the GAP activity of RGS4. These findings support GRK2 as a bona fide Gαq effector.\",\n      \"method\": \"Flow cytometry protein interaction assay (FCPIA), GAP assays, allosteric modulation measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (FCPIA + GAP assay) demonstrating ternary complex formation and allosteric effects; single lab\",\n      \"pmids\": [\"18936096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Diacylglycerol kinase zeta (DGKζ), which degrades DAG downstream of Gαq-PLCβ signaling, rescues Gαq transgenic mice from heart failure. DGKζ prevents cardiac dysfunction, attenuates PKC isoform translocation, and reduces JNK and p38 MAPK phosphorylation caused by activated Gαq.\",\n      \"method\": \"Double-transgenic mice (Gαq × DGKζ), echocardiography, PKC translocation assay, kinase phosphorylation assays, survival analysis\",\n      \"journal\": \"Circulation journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo (double transgenic rescue), multiple molecular readouts; single lab\",\n      \"pmids\": [\"18219172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mechanical stretch activates GRK2 in cardiac myocytes via a Gαq–angiotensin II AT1 receptor–PKCα pathway. PKCα phosphorylates GRK2 at Ser29, activating it. A GRK2(S29A) mutant abolishes stretch-induced GRK2 activation and restores adenylyl cyclase activity, defining the phosphorylation mechanism.\",\n      \"method\": \"Neonatal rat cardiomyocyte stretch model, mini-gene inhibition of Gαq coupling, shRNA knockdown of PKCα, GRK2(S29A) overexpression, cardiac-specific PKCα transgenic mice, adenylyl cyclase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation site mutagenesis (S29A) combined with KD, transgenic, and cell-stretch model; multiple orthogonal methods\",\n      \"pmids\": [\"20194499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The Gαq signal (constituted by Gαq and Gα11 in osteoblasts) is inhibitory to the anabolic action of PTH on bone. Osteoblast-specific Gαq/Gα11 double-knockout mice show enhanced PTH-induced bone formation, while constitutively active Gαq transgenic mice do not respond to PTH. The inhibitory mechanism involves membrane translocation of PKCδ.\",\n      \"method\": \"Osteoblast-specific Gαq/Gα11 double-KO mice, constitutively active Gαq transgenic mice, PTH injection experiments, bone histomorphometry, primary osteoblast cultures, PKCδ translocation assay, RGS2 overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — both gain- and loss-of-function in vivo, cell-autonomous confirmation in primary cultures, PKCδ mechanism identified\",\n      \"pmids\": [\"21345793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A somatic activating mutation in GNAQ (c.548G→A, p.R183Q) causes Sturge-Weber syndrome and port-wine stains. The R183Q mutation leads to constitutive activation of Gαq, modestly increasing ERK activity as shown by phosphorylation-specific antibodies and luciferase reporter assay upon transgenic expression of mutant Gαq.\",\n      \"method\": \"Whole-genome sequencing of paired affected/normal tissue, amplicon sequencing and SNaPshot assays in 97 samples, phosphorylation-specific antibodies for ERK, luciferase reporter assay\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — discovery by WGS validated across 97 samples with functional confirmation of downstream signaling activation\",\n      \"pmids\": [\"23656586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Mutant GNAQ/GNA11 (Q209 mutations) consistently activates both the PKC and MAPK pathways in uveal melanoma cells. PKC inhibition selectively suppresses MAPK signaling in GNAQ/GNA11-mutant (but not wild-type) melanoma, demonstrating that PKC is an intermediary between mutant Gαq and MAPK activation.\",\n      \"method\": \"PKC inhibitors (AEB071, AHT956), MEK inhibitors (PD0325901, MEK162), cell proliferation and apoptosis assays, western blotting for pathway activation, allograft and xenograft mouse models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological epistasis with two different PKC inhibitors, two MEK inhibitors, in vitro and in vivo; single lab\",\n      \"pmids\": [\"24141786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In GNAQ-mutant uveal melanoma, MAPK activation depends on Ras and is mediated by RasGRP3, which is overexpressed selectively in response to GNAQ/11 mutation. RasGRP3 activation requires PKCδ- and PKCε-dependent phosphorylation as well as PKC-independent, DAG-mediated membrane recruitment. PKCδ and PKCε are required and sufficient for MAPK activation downstream of mutant Gαq.\",\n      \"method\": \"shRNA knockdown, PKC isoform-specific analysis, RasGRP3 expression analysis, phosphorylation assays, DAG membrane recruitment assays, MAPK activation readouts\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific PKC isoforms identified by KD, mechanistic pathway order established with multiple readouts; single lab\",\n      \"pmids\": [\"28486107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Endothelial GNAQ p.R183Q constitutively activates PLCβ3 (a direct downstream effector of Gαq), leading to activation of PKC, NF-κB, and calcineurin signaling. This increases ANGPT2 and DSCR1.4 expression. EC-R183Q cells form enlarged blood vessels in mice, and ANGPT2 knockdown normalizes vessel size, identifying PLCβ3→ANGPT2 as a key mechanism for capillary malformation.\",\n      \"method\": \"Lentiviral expression of R183Q or WT GNAQ in endothelial colony-forming cells, bulk RNA-seq, quantitative PCR, immunostaining of human tissue, YM-254890 inhibitor, PLCβ3 siRNA, PKC inhibitor (AEB071), shRNA knockdown of ANGPT2, in vivo vessel formation assay in mice\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (inhibitors, siRNA, in vivo rescue by ANGPT2 KD), human tissue validation; defines pathway mechanism\",\n      \"pmids\": [\"34670408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Downstream of GNAQ-mutant Gαq, the RhoA signaling axis activates PKN (PRK, an AGC kinase), which converges with ROCK to control FAK (focal adhesion kinase) as a mediator of non-canonical Gαq-driven signaling. PKN inhibition by darovasertib synergizes with FAK inhibitors to halt uveal melanoma growth.\",\n      \"method\": \"High-throughput chemogenetic drug screen, kinase inhibitor profiling (darovasertib), PKN/ROCK/FAK pathway analysis, cell viability assays, in vitro and in vivo (mouse metastatic model) combination studies\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chemogenetic screen plus pathway validation with inhibitors; in vitro and preclinical in vivo; single lab\",\n      \"pmids\": [\"37858338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GNAQ/11 mosaic variants (including R183Q and Q209L) hyperactivate constitutive and ligand-induced intracellular calcium signaling in endothelial cells. The aberrant ligand-activated calcium signal is fueled by extracellular calcium influx through calcium-release-activated channels (CRAC). Allele-selective siRNA targeting the variant allele corrects both constitutive and ligand-activated calcium signaling, and a CRAC inhibitor rescues the ligand-activated signal.\",\n      \"method\": \"Two cellular models expressing GNAQ/11 variants, intracellular calcium imaging, allele-selective siRNA, CRAC channel inhibitor\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two cellular models, pharmacological and genetic rescue; identifies CRAC channels as mediators; single lab\",\n      \"pmids\": [\"37802293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Reporter assays comparing GNAQ variants (WT, R183Q, Q209L, Q209R, null) show Q209L has highest activation, while R183Q and Q209R show significantly lower but still activating levels. RNA-seq of microvascular endothelial cells shows all missense variants cause extensive transcriptomic dysregulation compared to WT or null, but R183 and Q209 variants show very few differentially expressed genes when compared to each other — differing in activation magnitude but having similar downstream effects.\",\n      \"method\": \"GNAQ-responsive luciferase reporter assay, RNA-seq in HMEC-1 cells electroporated with GNAQ variants\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct reporter assay plus RNA-seq in two experimental systems; single lab\",\n      \"pmids\": [\"35635655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The endothelial cell is the specific cell type enriched for the GNAQ p.R183Q mutation in skin capillary malformations (mutant allelic frequency 3–43% in CD31+ endothelial cells versus lower in other fractions), identifying endothelial cells as the source of aberrant Gαq signaling in capillary malformation.\",\n      \"method\": \"FACS fractionation of human capillary malformation tissue into endothelial, hematopoietic, perivascular, and stromal populations; droplet digital PCR for GNAQ p.R183Q\",\n      \"journal\": \"Plastic and reconstructive surgery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific fractionation plus highly sensitive ddPCR; 6 specimens fractionated; single lab\",\n      \"pmids\": [\"26368330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GNAQ T96S mutation (found in 8.7% of NK/T cell lymphoma) acts in a dominant-negative manner to promote tumor growth by suppressing Gαq-mediated inhibition of AKT and MAPK signaling. Conditional Gαq knockout in NK cells (Ncr1-Cre) demonstrates that Gαq deficiency enhances NK cell survival, identifying Gαq as a tumor suppressor in this context.\",\n      \"method\": \"Whole-exome/targeted deep sequencing, conditional KO mice (Ncr1-Cre-Gnaqfl/fl), NK cell survival assays, AKT and MAPK pathway activation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific cellular phenotype and pathway analysis; dominant-negative mechanism proposed with pathway data; single lab\",\n      \"pmids\": [\"31527657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hyperactive GNAQ mutation in endothelial cells (mouse model) drives vascular tumor growth with increased MAPK signaling. Trametinib (MEK inhibitor) suppresses tumor growth by reducing vascular cell proliferation and permeability and prevents coagulopathy.\",\n      \"method\": \"Endothelial-specific hyperactive GNAQ knock-in mouse model, transcriptomic analysis, Trametinib treatment, vascular phenotype and coagulopathy measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse model with transcriptomic pathway validation and pharmacological rescue; single lab\",\n      \"pmids\": [\"37024491\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GNAQ encodes the Gαq subunit of heterotrimeric G proteins, which couples activated GPCRs to phospholipase Cβ (particularly PLCβ1 and PLCβ3) via a pre-formed, stable complex at the plasma membrane; PLCβ activation generates DAG and IP3, leading to PKC activation and intracellular calcium release (via CRAC channels), with downstream activation of MAPK (through RasGRP3 via PKCδ/ε), RhoA (via LARG), and FAK (via PKN/ROCK); Gαq also inhibits PI3Kα/Akt through direct interaction; its activity is terminated by GRK2 and RGS proteins (RGS2, RGS4) acting allosterically; somatic activating mutations at Q209 (constitutively activating) or R183Q (moderately activating) drive uveal melanoma, blue naevi, and vascular malformations (Sturge-Weber syndrome, capillary malformations) by constitutively engaging these downstream cascades in melanocytes and endothelial cells, respectively, while germline loss-of-function reveals essential roles in platelet activation, cardiac development, hippocampal LTD, and dendritic cell chemotaxis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GNAQ encodes the Gαq subunit of a heterotrimeric G protein that couples agonist-activated GPCRs to phospholipase C, transducing receptor signals into intracellular calcium, DAG, and PKC activation; it does so selectively, coupling defined receptors such as the PTH/PTHrP, calcitonin, and gastrin-releasing peptide receptors to PLC in a manner that requires agonist and Gβγ and cannot be substituted by Gαi or βγ [#3, #4, #0]. Gαq engages PLCβ1 as a stable pre-associated complex that permits rapid, localized signaling upon activation [#11], and it recruits additional effectors including the RhoGEF LARG to activate RhoA [#7]; conversely, constitutively active Gαq directly binds and inhibits the p110α–p85α PI3K heterodimer independently of PLC [#9]. Its signaling output is constrained by GRK2, which binds active Gαq through its RGS domain in an activation-dependent manner via the Gαq C-terminus and acts as a bona fide effector, together with the Gβ5·RGS7 dimer and RGS2/RGS4, which form ternary complexes and allosterically modulate Gαq engagement of effectors [#8, #10, #17]. Through these cascades Gαq is essential for platelet activation by physiological agonists, for cardiac development, for mGluR-dependent hippocampal long-term depression, and for chemokine-driven calcium responses and chemotaxis in dendritic cells and granulocytes [#0, #1, #6, #12], and sustained Gαq activation drives cardiac hypertrophy and heart failure through DAG/PKC-dependent signaling that diacylglycerol kinase ζ can reverse [#2, #18]. Somatic activating mutations at codon Q209 turn GNAQ into a dominant oncogene in blue naevi and uveal melanoma, while the weaker R183Q mutation causes Sturge-Weber syndrome and capillary malformations; both activate downstream PKC–MAPK signaling via RasGRP3 and PKCδ/ε, RhoA–PKN/ROCK–FAK, and in endothelial cells PLCβ3-driven calcium influx through CRAC channels and ANGPT2 induction [#16, #21, #22, #23, #24, #25, #26]. In a contrasting context, the GNAQ T96S mutation acts dominant-negatively to relieve Gαq-mediated suppression of AKT/MAPK, identifying Gαq as a tumor suppressor in NK/T cell lymphoma [#29].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that Gαq is a functional PLC-coupling transducer for specific peptide-hormone GPCRs, defining its core molecular role of linking receptors to inositol phosphate generation.\",\n      \"evidence\": \"Receptor/Gα cotransfection reconstitution in COS-7/HEK293 with inositol phosphate accumulation assays\",\n      \"pmids\": [\"8732687\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish endogenous receptor pairings in native cells\", \"Did not resolve selectivity among Gαq family members in vivo\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved which receptors selectively recruit Gαq and showed agonist- and Gβγ-dependence of receptor-catalyzed nucleotide exchange, defining the biochemical activation step.\",\n      \"evidence\": \"In situ reconstitution with purified Gα subunits and GTP-γS binding for the GRP receptor\",\n      \"pmids\": [\"9012857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Limited to a single receptor in reconstituted membranes\", \"Did not link to downstream effector engagement\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated a non-redundant physiological requirement for Gαq in platelet activation, showing Gαi and βγ cannot substitute, and connecting Gαq to hemostasis.\",\n      \"evidence\": \"Germline Gαq-knockout mice with platelet aggregation, bleeding time, and thromboembolism assays\",\n      \"pmids\": [\"9296496\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the receptors/effectors mediating the platelet defect\", \"Whole-body KO confounds cell-autonomy\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined Gq-class requirement and redundancy in cardiac development and showed that excess Gαq activity is pathogenic, framing the dosage-sensitive role of Gαq in the heart.\",\n      \"evidence\": \"Gαq/Gα11 double-KO embryonic lethality and cardiac-specific Gαq overexpression transgenics with pressure overload\",\n      \"pmids\": [\"9687499\", \"9576430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not isolate the effector branch responsible for hypertrophy\", \"Redundancy with Gα11 obscures Gαq-specific contributions\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linked Gαq to PI3K-dependent metabolic signaling, showing constitutively active Gαq drives GLUT4 translocation via p110α.\",\n      \"evidence\": \"Antibody microinjection, Q209L overexpression, PI3K immunoprecipitation, and wortmannin inhibition in adipocytes\",\n      \"pmids\": [\"10490615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apparent positive PI3K link contrasts with later direct-inhibition finding\", \"Did not establish endogenous receptor input\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Established a required role for Gαq in synaptic plasticity, specifically mGluR-dependent hippocampal LTD but not LTP.\",\n      \"evidence\": \"Hippocampal slice electrophysiology in Gαq-KO mice with pharmacological and stimulation-based LTD/LTP induction\",\n      \"pmids\": [\"11438569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the downstream effector chain for LTD\", \"Constitutive KO precludes acute/developmental separation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified LARG as an effector coupling Gαq to RhoA, extending Gαq output beyond PLCβ to cytoskeletal/Rho signaling.\",\n      \"evidence\": \"Reciprocal co-IP with transition-state-mimetic Gα and RhoA activation/transformation assays\",\n      \"pmids\": [\"12024019\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP without structural mapping of the interaction\", \"Physiological relevance in tissue not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Clarified signal termination/effector machinery by showing GRK2 binds active Gαq via its RGS domain and Gβ5·RGS7 directly engages and inhibits Gαq.\",\n      \"evidence\": \"Pull-downs, chimeric Gαq mapping, FRET in live cells, and signaling assays\",\n      \"pmids\": [\"12885252\", \"12670932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Gβ5·RGS7 interaction requires unidentified cellular cofactors\", \"GRK2's dual effector/regulator roles not fully reconciled\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated a PLC-independent branch in which active Gαq directly inhibits p110α PI3K, defining a distinct biochemical effector relationship.\",\n      \"evidence\": \"In vitro kinase assays with purified p110α-p85α plus cellular co-IP using inducible Q209L-Gαq\",\n      \"pmids\": [\"12704201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with the adipocyte GLUT4/PI3K activation finding unresolved\", \"Structural basis of inhibition not determined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed Gαq and PLCβ1 exist as a stable pre-formed complex, explaining the rapid, localized kinetics of Gq signaling.\",\n      \"evidence\": \"Live-cell and in vitro FRET at near-endogenous expression in PC12/HEK293 cells\",\n      \"pmids\": [\"16754659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab FRET without orthogonal structural confirmation\", \"Stoichiometry and membrane microdomain context not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended Gαq's physiological roles to immune cell migration, cytoskeletal control, and tissue-specific differentiation, showing context-dependent effector use (PKC, calcineurin).\",\n      \"evidence\": \"Gαq-KO mice (DC/neutrophil chemotaxis), inhibitor/siRNA/Q209L approaches in keratinocytes, and transgenic/pharmacology in osteoblasts and adipocytes\",\n      \"pmids\": [\"17938235\", \"17609252\", \"17823129\", \"16888802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor inputs vary by tissue and were not uniformly mapped\", \"Downstream effector convergence across cell types not unified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified GNAQ Q209 mutations as constitutively activating oncogenic drivers in melanocytic neoplasia, establishing GNAQ as a dominant oncogene.\",\n      \"evidence\": \"Tumor sequencing of blue naevi/uveal melanoma with cell-based transformation/activation assays\",\n      \"pmids\": [\"19078957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not delineate the full downstream effector requirements for transformation\", \"Cell-of-origin specificity not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Refined Gαq's regulatory network and cardiac pathology mechanism: RGS2/RGS4–GRK2 ternary complexes allosterically modulate Gαq, and DAG kinase ζ rescues Gαq-driven heart failure.\",\n      \"evidence\": \"FCPIA/GAP assays for allosteric modulation and Gαq×DGKζ double-transgenic mouse rescue with PKC/MAPK readouts\",\n      \"pmids\": [\"18936096\", \"18219172\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab biochemistry for ternary complexes\", \"DGKζ rescue does not prove DAG is the sole pathogenic node\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a mechanotransduction circuit in which Gαq–AT1R–PKCα phosphorylates GRK2 at Ser29 to activate it, mechanistically linking Gαq signaling to GRK2 regulation.\",\n      \"evidence\": \"Cardiomyocyte stretch model with mini-gene Gαq inhibition, PKCα shRNA, GRK2-S29A mutant, and transgenic mice\",\n      \"pmids\": [\"20194499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific to cardiac stretch context\", \"Did not address feedback on Gαq signaling output\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established that Gαq/11 signaling antagonizes PTH anabolic action in bone via PKCδ translocation, demonstrating bidirectional control by gain- and loss-of-function in vivo.\",\n      \"evidence\": \"Osteoblast-specific Gαq/Gα11 double-KO and Q209L transgenic mice with PTH challenge, histomorphometry, and PKCδ assays\",\n      \"pmids\": [\"21345793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor coupling to the inhibitory output not fully mapped\", \"Cross-talk with Gs/cAMP arm not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the weaker R183Q activating mutation as the cause of Sturge-Weber syndrome and port-wine stains, expanding GNAQ disease beyond melanoma and linking mutation strength to phenotype.\",\n      \"evidence\": \"Whole-genome and amplicon sequencing of affected tissue with ERK phosphorylation and luciferase reporter validation\",\n      \"pmids\": [\"23656586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial mechanism not yet defined at this stage\", \"Quantitative relationship of activation strength to phenotype unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined PKC as the obligatory intermediary between mutant Gαq and MAPK in uveal melanoma, establishing a therapeutically actionable signaling axis.\",\n      \"evidence\": \"Pharmacological epistasis with PKC and MEK inhibitors plus in vitro/in vivo melanoma models\",\n      \"pmids\": [\"24141786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the specific Ras pathway link (addressed later)\", \"PKC isoform specificity unresolved at this stage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Pinpointed the endothelial cell as the cell type harboring GNAQ R183Q in capillary malformations, identifying the source of aberrant Gαq signaling.\",\n      \"evidence\": \"FACS fractionation of human malformation tissue with droplet digital PCR for R183Q\",\n      \"pmids\": [\"26368330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small specimen number\", \"Did not establish the downstream endothelial mechanism\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved the Ras-dependent route to MAPK in GNAQ-mutant melanoma, showing RasGRP3 (induced by mutant Gαq) is activated by PKCδ/ε phosphorylation and DAG-mediated recruitment.\",\n      \"evidence\": \"shRNA knockdown, PKC isoform analysis, DAG recruitment, and MAPK readouts in uveal melanoma cells\",\n      \"pmids\": [\"28486107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-lab; relative contribution of PKC-dependent vs DAG-dependent recruitment not quantified\", \"Generality across other Gαq-mutant tissues untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a context-dependent tumor-suppressor role for Gαq, where the dominant-negative T96S mutation relieves Gαq-mediated inhibition of AKT/MAPK to promote NK/T lymphoma.\",\n      \"evidence\": \"Sequencing, conditional Ncr1-Cre Gαq KO mice, and NK cell survival/pathway assays\",\n      \"pmids\": [\"31527657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative mechanism inferred from pathway data, not structurally proven\", \"Single-lab; reconciliation with oncogenic Gαq roles incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Quantified the activation hierarchy of GNAQ variants, showing R183 and Q209 mutations differ mainly in activation magnitude while producing similar downstream transcriptomes.\",\n      \"evidence\": \"GNAQ-responsive luciferase reporter and RNA-seq across variant panel in microvascular endothelial cells\",\n      \"pmids\": [\"35635655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reporter readout may not capture all effector branches\", \"Phenotypic divergence despite similar transcriptomes unexplained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined effector mechanisms and therapeutic vulnerabilities of mutant Gαq across vascular and melanoma contexts: endothelial PLCβ3→ANGPT2 and CRAC-mediated calcium influx in malformations, RhoA→PKN/ROCK→FAK in melanoma, and MAPK-driven vascular tumor growth.\",\n      \"evidence\": \"Endothelial R183Q/knock-in models, RNA-seq, allele-selective siRNA, CRAC/PKC/MEK/PKN/FAK inhibitors, ANGPT2 knockdown, and in vivo rescue\",\n      \"pmids\": [\"34670408\", \"37858338\", \"37802293\", \"37024491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each mechanism shown largely single-lab\", \"Relative dominance of parallel effector branches per tissue not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple parallel Gαq effector branches (PLCβ/PKC-MAPK, RhoA-FAK, direct PI3K inhibition, CRAC-calcium) are differentially weighted to produce distinct cell-type- and mutation-specific phenotypes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking effector usage to tissue-specific outcome\", \"Structural basis distinguishing R183Q vs Q209 signaling magnitude not defined\", \"Reconciliation of Gαq's oncogenic vs tumor-suppressor roles across cell types incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 4, 0]},\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 21, 22, 29]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\"Gq heterotrimeric G protein\"],\n    \"partners\": [\"PLCB1\", \"PLCB3\", \"GRK2\", \"ARHGEF12\", \"PIK3CA\", \"RGS2\", \"RGS4\", \"GNB5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}